Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
IMVT - Immunovant, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.00
DETAILS
HIGH:
$40.00
LOW:
$40.00
MEDIAN:
$40.00
CONSENSUS:
$40.00
UPSIDE:
0.73%
Stock News
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.
Immunovant Q4 Earnings Call Highlights
Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m.
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total transaction of $81,573.48. Following the completion of the sale, the chief technology officer directly owned 251,685 shares in the
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Institutional and Insider Ownership 92.9% of Arcus Biosciences
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint. Brepocitinib expands into lichen planopilaris Matt Gline, CEO of Roivant Sciences, said the companies are moving
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant's treatment for eye disease fails late-stage trial
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib's expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026 Immunovant's Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves' disease Immunovant remains focused on rapid advancement of IMVT-1402 in multiple indications Roivant will host an investor call to discuss these updates today, April 2, 2026, at 8:00 a.m.
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
Price Targets
Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright
$40.00
(was $35.56)
Douglas Tsao
·
H.C. Wainwright
Immunovant upgraded to Outperform at Wolfe on improving Graves' perception
$50.00
(was $24.97)
Wolfe Research
Immunovant price target lowered to $41 from $44 at Guggenheim
$41.00
(was $26.27)
Yatin Suneja
·
Guggenheim
Immunovant initiated with a Hold at Truist
$16.00
(was $17.35)
Truist Financial
H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)
$51.00
(was $30.20)
Douglas Tsao
·
H.C. Wainwright
Immunovant price target lowered to $46 from $50 at Oppenheimer
$46.00
(was $25.39)
Leland Gershell
·
Oppenheimer
Immunovant (IMVT) PT Lowered to $48 at Guggenheim
$48.00
(was $26.41)
Yatin Suneja
·
Guggenheim
Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)
$57.00
(was $27.83)
Yasmeen Rahimi
·
Piper Sandler
Goldman Sachs Starts Immunovant (IMVT) at Buy
$50.00
(was $31.82)
Corinne Johnson
·
Goldman Sachs
Immunovant downgraded to Neutral from Buy at UBS
$5.00
(was $4.88)
Colin Bristow
·
UBS